Corpus Intelligence IC Memo — CHESTNUT HILL BENEVOLENT ASSOCIATION 2026-04-26 09:05 UTC
IC Memo — CHESTNUT HILL BENEVOLENT ASSOCIATION
Investment Committee Memorandum | MA | 20 beds | Grade D | EBITDA uplift $224K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CHESTNUT HILL BENEVOLENT ASSOCIATION

CCN 221990 | NORFOLK, MA | 20 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

CHESTNUT HILL BENEVOLENT ASSOCIATION is a 20-bed community hospital in NORFOLK, MA with $2.8M in net patient revenue and a -100.0% operating margin. The hospital serves a payer mix of 51.3% Medicare, 0.0% Medicaid, and 48.7% commercial.

Thesis: Turnaround. Our ML models identify $224K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -100.0% to -202.8% (+787bps).

Net Revenue HCRIS$2.8M
Current EBITDA COMPUTED$-6.0M
Operating Margin COMPUTED-100.0%
Occupancy HCRIS17.3%
Revenue / Bed COMPUTED$142K
Net-to-Gross HCRIS100.0%
Distress Probability MLnan%

2. Market Context & Competitive Position

99
MA Hospitals
-12.2%
State Median Margin
9
Comparable Hospitals

MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of -100.0% places it below the state median. Among 9 size-comparable peers (10-40 beds), the median margin is -16.8%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (10-40), prioritizing same-state peers. 9 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CHESTNUT HILL BENEVOLENT ASSOC (Target)MA20$2.8M-100.0%
DANA-FARBER CANCER INSTITUTEMA30$1.88B-35.1%
MARTHAS VINEYARD HOSPITALMA25$121.6M3.2%
FAIRVIEW HOSPITALMA24$94.5M19.8%
BAYSTATE WING HOSPITAL & MEDICMA40$91.8M-16.8%
NANTUCKET COTTAGE HOSPITALMA14$65.3M-25.8%
ATHOL MEMORIAL HOSPITALMA21$30.3M-26.1%
WHITTIER HOSPITAL-BRADFORDMA35$27.6M-5.1%
CORRIGAN MENTAL HEALTH CENTERMA16$nannan%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $224K (787bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Denial Rate Reduction12.0%6.5%$63K+221bp12mo
Net Collection Rate93.5%97.0%$60K+210bp18mo
Cost to Collect4.5%2.5%$57K+200bp12mo
A/R Days Reduction5200.0%3800.0%$35K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+34bp6mo

5. EBITDA Bridge

Denial Rate Reduction
$63K
Net Collection Rate
$60K
Cost to Collect
$57K
A/R Days Reduction
$35K
Clean Claim Rate
$10K
Total EBITDA Uplift$224K
Current EBITDA$-6.0M
+ RCM Uplift+$224K
Pro Forma EBITDA$-5.8M
Current Margin-100.0%
Pro Forma Margin-202.8%
WC Released (1x)$109K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-9.2M$-37.3M0.00x-100.0%
Base (11x exit)10.0x11.0x$-9.2M$-44.0M0.00x-100.0%
Bull Case9.0x11.0x$-8.3M$-46.3M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-8.3M$-53.0M0.00x-100.0%
Bear Case11.0x10.0x$-10.1M$-35.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-10.1M$-42.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 17.3%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 9 hospitals with 10-40 beds
  • Same-state prioritization (n=10)
  • Comp margins: P25=-26.0% / P50=-16.8% / P75=-1.0%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.